+44 (0) 1223 755950
+1 832 327 7413
Click on the image to see the image legend
Target | VZV ORF9 (Dumas) |
Origin | Virus |
Expression | Recombinant |
Tested Applications | ELISA, WB |
Host | E. coli |
Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
Conjugation | Unconjugated |
Form | Liquid |
Purity | > 95% (10% PAGE with Coomassie staining) |
Purification | Purified from E. coli by GS-4B Sepharose Affinity Purification. |
Storage | Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles. |
Sequence Fragment | Contains the VZV ORF9 immunodominant regions. |
Sequence | The exact sequence is proprietary. |
Tag | Contains GST fusion partner. |
Buffer | 25 mM Tris-HCl, 1 mM EDTA containing 50% Glycerol. Does not contain preservatives. |
Specificity | Immunoreactive with VZV positive sera. |
Concentration | 1 mg/ml |
Availability | Shipped within 10-20 working days. |
Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Directions for use | Centrifuge before opening to ensure complete recovery of vial contents. |